Figure 2 | Scientific Reports

Figure 2

From: Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer

Figure 2

Assessment of 516 FDA-approved and clinically used drugs on parental and erlotinib-resistant WHIM2 PDXs. Tumors were excised from mice, prepped into single cell suspensions, plated in 96-well dishes, and treated with 10 μM of drug. Cell viability was assessed with CellTiter-Glo after 72 h of treatment and normalized to DMSO vehicle control. Parental (n = 3) and erlotinib-resistant (n = 3) tumors were treated in triplicate.

Back to article page